Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
一项开放标签、随机、III期ASPIRE试验评估了卡非佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗复发性多发性骨髓瘤患者的疗效,结果显示,这些患者的健康相关生活质量与卡非佐米、来那度胺和地塞米松联合治疗效果相当。
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2016.66.9648
Stewart, A Keith; Dimopoulos, Meletios A; Masszi, Tamás; Špička, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David S; Niesvizky, Ruben; Jakubowiak, Andrzej J; San-Miguel, Jesus F; Ludwig, Heinz; Buchanan, Jacqui; Cocks, Kim; Yang, Xinqun; Xing, Biao; Zojwalla, Naseem; Tonda, Margaret; Moreau, Philippe; Palumbo, Antonio